Last reviewed: June 5, 2026
Last updated: June 5, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Both semaglutide and tirzepatide have shown significant weight reduction in clinical trials, but they work through distinct biological mechanisms. Understanding how each medication functions can help you and your provider determine which approach aligns with your metabolic profile and weight loss objectives.
How Semaglutide Works for Weight Loss
Semaglutide is a GLP-1 receptor agonist, meaning it activates a single pathway in your body that regulates appetite and blood sugar. When semaglutide binds to GLP-1 receptors in the brain and gut, it slows stomach emptying, increases feelings of fullness, and reduces hunger signals. This mechanism has been studied extensively, with trials showing average weight reductions of 10–15% of body weight over 68 weeks in patients with obesity.
The medication works best when combined with consistent lifestyle changes including dietary modifications and increased physical activity. Many patients report that semaglutide makes adherence to a calorie-reduced diet easier because appetite suppression occurs naturally rather than through willpower alone. PlexusDx offers compounded semaglutide in both injection and oral formulations, allowing flexibility based on your preference and tolerance.
The Dual-Receptor Advantage of Tirzepatide
Tirzepatide activates two receptor pathways simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual-receptor approach creates a more comprehensive metabolic effect than single-pathway GLP-1 agonists. Clinical trials have demonstrated that tirzepatide produces greater average weight loss—up to 20–22% of body weight—compared to semaglutide alone, with the advantage appearing more pronounced at higher dose levels.
The GIP receptor activation in tirzepatide enhances insulin secretion when glucose is high, improves energy expenditure, and may provide additional appetite suppression through a different neural pathway. This combination allows tirzepatide to address multiple hunger and satiety mechanisms simultaneously. PlexusDx delivers compounded tirzepatide injections starting at $249/month, with oral formulations also available for patients who prefer non-injectable administration.
Key Differences in Weight Loss Efficacy
Head-to-head comparison trials show that tirzepatide consistently achieves numerically greater weight loss than semaglutide at equivalent time points. In the SURPASS-2 trial, patients on tirzepatide lost approximately 20.9% of body weight versus 16.0% on semaglutide (both at comparable doses) over 40 weeks. However, individual response varies significantly based on genetics, lifestyle, baseline metabolic factors, and adherence.
Some patients achieve their weight loss goals with semaglutide alone and prefer its established safety profile or lower entry price. Others respond better to tirzepatide's dual-mechanism approach, particularly if they have insulin resistance or metabolic syndrome components. PlexusDx's Precision Peptide Genetic Test identifies genetic variants in GLP1R, GIPR, FTO, and MC4R pathways that may predict which mechanism aligns better with your individual peptide responsiveness across 14 metabolic pathways.
Cost, Convenience, and Personalized Selection
PlexusDx compounded semaglutide injections start at $149 per month, while tirzepatide injections begin at $249 per month. Your dose may need to go up as you progress through treatment—your price won't. Both medications are available without insurance requirements, are HSA/FSA eligible, and ship to all 50 states from licensed 503A compounding pharmacies meeting rigorous pharmaceutical standards.
Choosing between semaglutide and tirzepatide involves weighing cost, expected efficacy, injection frequency preferences, and your individual health profile. PlexusDx providers can incorporate genetic insights through the Precision Peptide Genetic Test ($99 add-on after your first month) to identify peptide-pathway predispositions that may inform whether semaglutide's single-receptor approach or tirzepatide's dual mechanism better matches your metabolic genetics. PlexusDx also offers GLP-Squared, a dual-compound injection combining both medications for advanced metabolic control starting at $249 per month.
Side Effects and Tolerability Considerations
Both semaglutide and tirzepatide commonly cause gastrointestinal side effects including nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. These effects are typically mild to moderate and tend to diminish over 2–4 weeks as your body adjusts. Some patients tolerate one medication better than the other due to individual gut sensitivity and genetic factors affecting peptide receptor expression.
Serious adverse events including pancreatitis, gallbladder disease, and severe dehydration are rare but require medical monitoring. PlexusDx patients receive ongoing provider support to manage side effects, adjust dosing protocols, and determine whether a medication switch might improve tolerability. The microdose GLP-1 protocol ($129/month) offers a gentler entry option for patients concerned about initial side effects or those seeking lower-intensity metabolic support.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Which medication causes more weight loss—semaglutide or tirzepatide?
Clinical trials show tirzepatide produces greater average weight loss (20–22% of body weight) compared to semaglutide (10–15%), primarily due to its dual GLP-1 and GIP receptor activation. Individual results vary significantly based on genetics, lifestyle adherence, and metabolic factors. PlexusDx providers can discuss whether tirzepatide's additional efficacy justifies its $249/month starting cost versus semaglutide's $149/month entry price for your specific goals.
Can I switch from semaglutide to tirzepatide if I'm not seeing results?
Yes, switching between medications is a common clinical strategy if one isn't meeting your weight loss targets or if tolerability becomes an issue. Your PlexusDx provider can design a transition protocol to safely switch therapies while minimizing side effects. Some patients benefit from tirzepatide's dual-receptor mechanism after plateauing on semaglutide alone.
Is tirzepatide more expensive than semaglutide with PlexusDx?
Tirzepatide injections start at $249/month compared to semaglutide injections starting at $149/month—a $100 monthly difference. Both medications maintain flat pricing across dose increases, so your price won't rise as your dose adjusts. Oral formulations of both are also available, with tirzepatide oral starting at $279/month.
What genetic factors predict whether I'll respond better to semaglutide or tirzepatide?
PlexusDx's Precision Peptide Genetic Test identifies key variants in GLP1R, GIPR, FTO, and MC4R pathways that influence your peptide responsiveness across 14 metabolic mechanisms. Certain genetic predispositions may suggest stronger benefit from tirzepatide's GIP activation, while others may indicate excellent response to semaglutide's single-pathway approach. This $99 add-on test, available after your first month, supports truly personalized medication selection.
Are compounded semaglutide and tirzepatide from PlexusDx as safe as brand-name versions?
PlexusDx medications are manufactured by licensed 503A compounding pharmacies operating under strict pharmaceutical quality standards. While compounded medications are not FDA-approved like brand versions, 503A compounds are legally required to meet identical purity, potency, and sterility standards. Your PlexusDx provider monitors safety and efficacy throughout treatment with ongoing clinical support.
Can I use HSA or FSA funds to pay for PlexusDx medications?
Yes, both semaglutide and tirzepatide from PlexusDx are HSA and FSA eligible, reducing your out-of-pocket cost if you have these tax-advantaged accounts. PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization, making precision GLP-1 therapy accessible regardless of your coverage status.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What Medications Can You Not Take with GLP-1 Agonists?
How Much B12 is in Compounded Semaglutide? Exploring the Synergy Between Two Powerhouses